title: [Diagnosis and treatment with steroids for patients with Duchenne muscular dystrophy: experience and recommendations for Mexico. Administración del Patrimonio de la Beneficencia Pública. Asociación de Distrofia Muscular de Occidente].
abstract: Duchenne muscular dystrophy is a severe, debilitating and progressive disease that affects 1 in 3,500 live male births in the world. The diagnosis should be confirmed by genetic testing to identify the mutation in the DMD gene or muscle biopsy and immunostaining to demonstrate the absence of dystrophin. Although up to now continues to be an incurable disease, this does not mean it has no treatment. Treatment should be multidisciplinary, looking for the functionality of the patient and avoiding or correcting complications, mainly cardio-respiratory and skeletal. Many proposals have been evaluated and implemented with the aim of improving the quality of life for these patients. The long-term steroids have shown significant benefits, such as prolonging ambulation, reduce the need for spinal surgery, improve cardiorespiratory function and increase survival and the quality of life. This document presents the recommendations based on the experience of the working group and experts worldwide on the diagnosis and treatment with steroids for patients with Duchenne muscular dystrophy.
authors.affiliation: Asociacion de Distrofia Muscular de Occidente, Jalisco, Mexico.
authors.forename: Norma A
authors.initials: NA
authors.lastname: Vázquez-Cárdenas
authors.forename: Francisco
authors.initials: F
authors.lastname: Ibarra-Hernández
authors.forename: Luz B
authors.initials: LB
authors.lastname: López-Hernández
authors.forename: Rosa E
authors.initials: RE
authors.lastname: Escobar-Cedillo
authors.forename: Luis A
authors.initials: LA
authors.lastname: Ruano-Calderón
authors.forename: Benjamín
authors.initials: B
authors.lastname: Gómez-Díaz
authors.forename: Noemí
authors.initials: N
authors.lastname: García-Calderón
authors.forename: M Fernanda
authors.initials: MF
authors.lastname: Carriedo-Dávila
authors.forename: Liliana G
authors.initials: LG
authors.lastname: Rojas-Hurtado
authors.forename: Emilia
authors.initials: E
authors.lastname: Luna-Padrón
authors.forename: Ramón M
authors.initials: RM
authors.lastname: Coral-Vázquez
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017028:Caregivers / Q000193:education; D003131:Combined Modality Therapy; D003937:Diagnosis, Differential; D016189:Dystrophin / Q000235:genetics; D006331:Heart Diseases / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006943:Hyperglycemia / Q000139:chemically induced; D007165:Immunosuppression Therapy; D015994:Incidence; D008297:Male; D008800:Mexico / Q000453:epidemiology; D025202:Molecular Diagnostic Techniques; D020388:Muscular Dystrophy, Duchenne / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics / Q000534:rehabilitation; D009765:Obesity / Q000139:chemically induced; D010348:Patient Care Team; D026741:Physical Therapy Modalities; D011788:Quality of Life; D012131:Respiratory Insufficiency / Q000209:etiology / Q000517:prevention & control; D012138:Respiratory Therapy
chemical_list: D000305:Adrenal Cortex Hormones; C484258:DMD protein, human; D016189:Dystrophin